The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:

  • To share (anonymized) case studies of how quantitative decision-making methods have been used within pharmaceutical companies, for decisions at the trial level, at the development level and at the portfolio level
  • To perform literature reviews, discuss and make recommendations on existing methodologies in terms of approach and interpretation
  • To develop new methodologies or practices where needed
  • To promote the role of the statistician in supporting decision-making in pharmaceutical companies and/or other stakeholders
  • To propose trainings, public meetings or publications to share methods and experience

For further information, or to join the QDM SIG, please contact the co-chairs:

Pierre Colin (Sanofi)
pierre.colin@sanofi.com

and

Gaelle Saint-Hilary (Politecnico di Torino)
gsainthilary@gmail.com

EventsFuture Events


  • A PSI Training Course on Improving Influence and Increasing Impact: Communication Skills for Industry Statisticians - Dates: 16 – 16 Sep, 2019

    This 1-day course will lead participants, in a non-threatening and encouraging atmosphere through steps to focus on improving the key skills of making impactful verbal and written communications.
  • PSI Webinar: Adaptive design: updated draft FDA guidance and its implications - Dates: 04 – 04 Jul, 2019

    In September 2018 the FDA published a guidance on adaptive design for clinical trials of drugs and biologics, updating (not finalizing) its initial draft from February 2010. The main focus of the webinar will be to provide an overview of its main contents, which will be presented by Jürgen Hummel (PPD). In addition, Kaspar Rufibach (Roche) will introduce an open-source statistical software for adaptive designs, RPACT (an R package that enables the design and analysis of confirmatory adaptive clinical trials). Kit Roes will also comment on the guidance from a European Regulatory perspective, which will be followed by a brief panel discussion.
MSD Logo Color

Statistics and Statistical Programming Opportunities at MSD

read more...

Costello Logo_RGB JPG

Statistics at Costello Medical

read more...

Pharm Research Associates

Principal Biostatistician

read more...

Autolus Therapeutics

Head of Statistical and Data Innovation as Head of Biometrics

read more...

bayerlogoresized

Statistician Opportunities in the UK

read more...